Until 2002, MHT was prescribed widely because it was believed that, apart from symptom relief, its use also prevented conditions such as cardiovascular disease and dementia. However, the Women's Health Initiative randomised placebo-controlled trial (RCT) published in 2002 found that the global harms (cancer and non-cancer outcomes) of taking MHT outweighed the benefits. 3 These results reduced the prevalence of MHT use among Australian women considerably, 4 but estimates suggest that more than 15% of Australian women aged between 50 and 65 currently use MHT. 5 Associations between MHT and cancer vary according to body site and whether oestrogen is used alone or in combination with a progestogen. It is likely that at least some of the observed associations with cancer result from the effects of these hormones on cell proliferation in the various target tissues. The International Agency for Research on Cancer (IARC) first concluded that there was sufficient evidence that oestrogen-only MHT was carcinogenic to humans in 1999. 6 In a subsequent report published in 2012, IARC also concluded that there was sufficient evidence that oestrogen plus a progestogen (combined MHT) was carcinogenic; however, they additionally found that there was sufficient evidence that oestrogen-only MHT decreases the risk of colorectal cancer (CRC). There is no consistent evidence that either vaginal oestrogens or tibolone (a synthetic molecule with oestrogenic, progestogenic and androgenic properties used for MHT) cause cancer, and IARC has not published evidence summaries
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relating these factors to cancers in humans. For these reasons, we reduced the prevalence estimate for MHT accordingly. Cancer associations by body site, MHT type and the level of evidence supporting them (according to IARC 7 ) are summarised in Table 1 .
This study aimed to estimate the number and proportion (population attributable fraction -PAF) of cancers diagnosed in Australian women in 2010 that could be attributed to the use of MHT and the number and proportion of cancers theoretically prevented by MHT use, according to MHT type.
Methods
The population attributable fraction of cancers associated with MHT is the proportion of cancers diagnosed in a given period in a specified population that could potentially have been avoided if no one in the population had used MHT. 8 We have also calculated the prevented fraction of cancers to estimate the proportion of cancers that would otherwise have occurred in the absence of any MHT use, but were prevented through prevailing use of MHT by Australian women.
In our primary analysis, we included cancers for which IARC concluded there was sufficient evidence of a causal association. Where highquality evidence published subsequent to the IARC report has strongly supported additional associations, we conducted supplementary analyses including these (see supplementary analysis section below). Analyses were conducted by type of MHT (oestrogenonly and combined). We estimated the proportion and number of breast cancers diagnosed in 2010 attributable to the use of combined MHT. We did not include endometrial cancer in the primary analysis because available Australian data do not provide estimates of the number of days per cycle that women were taking progestogens with oestrogen. We did, however, make a range of assumptions about the prevalence of progestogen use and modelled the likely effect of combined HRT on endometrial cancer in a supplementary analysis. For oestrogen-only MHT we estimated the proportion and number of endometrial and ovarian cancers diagnosed in 2010 attributable to its use and modelled the prevented fraction for colorectal cancer.
Relative risk estimates
As IARC did not publish pooled or summary estimates, 7 relative risks for the PAF calculations were sourced from metaanalyses, pooled analyses or from large cohort studies that published relative risks by MHT type and patterns of use reflecting the IARC conclusions (Table 1) . Relative risks from the Women's Health Initiative (WHI) RCT were not used because the participants were, on average, older (mean age 63 years at study entry) than the average post-menopausal woman using MHT and the mean duration of MHT use was limited to five years. 3 Similarly, we did not use estimates from the largest pooled analysis of the association between MHT use and ovarian cancer, 9 because no estimates of risk of ovarian cancer by duration of use were presented separately for oestrogen-only and combined MHT. We did, however, conduct a sensitivity analysis using the estimates from this study for both types of MHT combined. To assess the effect on the PAF of alternative relative risk estimates we conducted a sensitivity analysis using relative risks from other large cohort studies (studies summarised in the supplementary file: Table S1 , available with the online version of this article). The results of this analysis are presented in Table 3 .
Exposure prevalence estimates
No latent period was assumed in relation to MHT use, as current and recent use seem to confer the greatest risks. Risk also varies with duration of use and formulation; however, no single data source has captured nationally representative prevalence data cross-classified by these characteristics, so we used data from several different sources to derive prevalence estimates. We made several important assumptions in these derivations (described below). Table 2 . We assumed that the distribution of MHT type did not vary by age. Our estimates of prevalence of systemic MHT use were dependent on the assumptions we made about the prevalence of vaginal oestrogen use. As there are no nationally representative data on this, we conducted sensitivity analyses using a range of prevalence estimates to determine the likely impact on the PAF (see online supplementary file: Table S3 ).
Women who have had a hysterectomy are usually prescribed oestrogen-only MHT because they are no longer at risk of In that study, 13% of women who reported using oestrogen-only MHT had not had a hysterectomy. We applied this proportion to the estimated number of Australian women (by age group) taking oestrogen-only MHT (online supplementary file: Table S1 ) to separate oestrogen users who had had a hysterectomy from those who had not. Because the response proportion among controls in the AOCS was lower than ideal, we also conducted sensitivity analyses in which we recalculated the PAF assuming that: a) a higher proportion of women using oestrogen-only HRT had an intact uterus (25%); and b) a lower proportion of women using oestrogen-only HRT had an intact uterus (5%).
An adjustment could not be made to account for women with a bilateral oophorectomy, who would not be at risk of ovarian cancer, as suitable data on oophorectomy prevalence were not available.
Statistical analysis
To estimate the PAF, we used the standard formula:
where ERR x is the excess relative risk and P x is the prevalence of MHT use by age and/or duration category.
For cancers of the breast and endometrium, relative risks were available within strata of duration of use (<5 yrs, ≥5 yrs use). The excess relative risk for each stratum (x) was simply (RR x -1).
To calculate the PAF for endometrial cancer associated with oestrogen-only MHT use, the estimated proportions of women with an intact uterus currently taking oestrogen-only MHT (<5 yrs, ≥5 yrs) were used, assuming the duration of use did not differ by hysterectomy status.
For ovarian cancer, where the relative risks were estimated per year of MHT use, we calculated the excess relative risk using the dose-response relative risk and the mid-point of each duration category (in years): To estimate the number of cancers prevented by use of MHT, the formula was:
where N x is the number of observed cancers in 2010 in each age category and PF x is the prevented fraction in each age category.
The sum of the estimated number of prevented cancers across age categories was expressed as a percentage of the total observed plus total estimated prevented cancers.
Supplementary analysis
Based on evidence published [16] [17] [18] [19] [20] [21] Table1 summaries the relative risks used for these supplementary analyses.
Potential impact of reducing MHT use by Australian women
It is unrealistic to expect that no women will use MHT in the future. Briefly, for each cancer site, we calculated the number of cases that would have occurred in Australia in 2010 assuming that the alternative scenario of MHT use had prevailed. The PIF is then the proportional difference between the observed number of cancers and the number expected under the alternative prevalence scenario.
Potential impact of women only being prescribed oestrogen-only MHT
In 2010, breast cancer was the most common cancer in Australian women, accounting for 28% of all cancers diagnosed in women. Combined MHT confers a greater risk of breast cancer than oestrogen-only MHT, so we modelled possible effects on cancer incidence if women were only ever prescribed oestrogen-only MHT; that is, progestogens were not prescribed, even in women with 
Results
Estimates of the prevalence of current MHT use, by type and age category, in Australian women aged over 40 years in 2004-05 (assumed to apply in 2010) are presented in Table 2 . Prevalence of current use of MHT was highest among women in the 50-64 year age groups (peaking at 18% in the 55-59 year age group) but was reported by less than 5% of women in the youngest and oldest age groups. The estimated proportions of women using vaginal oestrogen only, systemic oestrogen-only MHT, or combined oestrogen and progestogen were similar at around 3% each. We estimated that 1% of women were currently taking tibolone. For all age groups over 55 years, the majority of current users had taken MHT for five years or more.
We estimate that 539 cancers (453 breast, 67 endometrium and 19 ovary) diagnosed in 2010 in women aged over 40 years were attributable to the current use of MHT. This was 1.1% of all cancers (excluding basal cell carcinoma and squamous cell carcinoma of the skin) diagnosed in women aged over 40 years (3.4%, 3.1% and 1.6% of breast, endometrial and ovarian cancers respectively) ( Table 3 ). In contrast, an estimated 52 colorectal cancers were prevented in women aged 40+ years through use of oestrogenonly MHT (Table 3) .
Sensitivity analyses
The results of our sensitivity analyses are presented in Table 3 . Under the various scenarios the proportion of all breast cancers attributable to use of combined MHT varied between 2.5% and 3.9%; the proportion of all endometrial cancers attributable to oestrogen-only MHT varied between 1.0% and 5.8%; and the proportion of ovarian cancers attributable to oestrogen-only MHT varied between 1.6% and 1.9%. Applying the relative risks for ovarian cancer from the recent pooled analysis 9 and using prevalence of both combined and oestrogen-only MHT users gave a PAF of 2.4%. The assumption that © 2015 The Authors resulted in the largest variation in the number of cancers attributed to MHT was whether women who used only vaginal oestrogen actually reported being current MHT users (539 in the primary analysis where we assumed all women using vaginal oestrogen reported being current users versus 631 cancers in the sensitivity analysis where we assumed only 50% did). For endometrial cancer the largest variation in estimated numbers of cancers resulted from varying the proportion of women using oestrogen-only MHT who had not had a hysterectomy from 13% to a low of 5% and a high of 25% (67 in the primary analysis; 31-127 in the sensitivity analysis).
Supplementary analyses
If associations between oestrogen-only MHT and breast cancer and combined MHT and ovarian cancer are causal, then an additional 127 (0.9%) breast cancers and 8 (0.7%) ovarian cancers could be attributed to MHT use.
Similarly, assuming a protective effect of combined MHT use on colorectal cancer, we estimated an additional 36 cases of colorectal cancer were prevented in 2010 through the use of combined MHT. When we applied the same relative risk to the Australian data as was used in the UK PAF project for current use of combined MHT and endometrial cancer, an estimated four cases of endometrial cancer in 2010 were prevented through combined MHT use. 
Potential impact of reducing MHT use by Australian women

Potential impact of women only being prescribed oestrogen-only MHT
Overall (in primary and supplementary analyses), we estimated that 670 cancers diagnosed in 2010 were attributable to the use of oestrogen-only or combined MHT. If women had only been prescribed oestrogenonly MHT, we estimate that the number of endometrial and ovarian cancers would have increased by 71 and 12 respectively; however, an estimated 323 fewer breast cancers would have occurred, and the overall total number of cancers attributable to use of MHT would be 430, a net reduction of 240 cancers.
Discussion
Our analyses suggest that more than 500 Australian women -and perhaps as many as 675 women -developed cancer in 2010 as a consequence of using MHT. On the other hand, an estimated 50 colorectal cancers were prevented in 2010 by oestrogen-only MHT; and if combined MHT also has a protective effect, then a further 36 colorectal and four endometrial cancers were likely prevented. The PAF was highest for breast (3.4%) and endometrial cancer (3.1%). In absolute terms, most of the cancers attributable to MHT use were breast cancers (n=453).
Other published studies have reported different PAFs for these hormonal exposures, reflecting different relative risk estimates and different prevalence of MHT use between countries. For example, the proportion of French women (45+ years) estimated to be using combined MHT (18.8%) 26 was much higher than that estimated for the Australian population (3.1%), leading to a much higher breast cancer PAF. 26 In contrast, the UK PAF project 23 reported lower PAFs for all cancers (3.2% for breast, 1.2% endometrium and 0.7% ovary) because prevalence of MHT use was lower. 23 While the precise mechanisms through which MHT causes cancers in humans are not known with certainty, the likely pathway to carcinogenesis in breast, endometrial and ovarian cancer is through oestrogeninduced cell proliferation with consequent increased risk of DNA damage and neoplastic transformation. 27 In breast cells, the presence of a progestogen substantially increases the rate of proliferation. In endometrial tissue, progestogens have the reverse effect, which is why the number of days per cycle that a progestogen is given as part of a MHT regimen determines the overall effect on risk of endometrial cancer. 27 We also made assumptions about use by women who have had a hysterectomy. We assumed that women with a hysterectomy all used oestrogen-only MHT. We also assumed that use of oestrogen-only MHT by the control women who participated in the Australian Ovarian Cancer Study was representative of the general population in that 13% of oestrogen-only users had an intact uterus; the true figure may be higher or lower. Furthermore, we were unable to take into consideration the possibility that some of these women may have been using progestogen-releasing intrauterine devices, to reduce their risk of endometrial neoplasia. Finally, information on duration of MHT use was only available for current users. While that is appropriate for breast and endometrial cancer calculations because risk is not elevated among former users, the doseresponse relative risk used for ovarian cancer was not restricted to current users, thus we may have underestimated the number of ovarian cancers attributable to former use.
The overall effect of the many assumptions that we made is difficult to quantify. However, the series of sensitivity analyses that we performed suggest relatively minor variations in the numbers of cancers attributable to MHT use under the various scenarios.
The largest change in the number of cancers attributable to use of MHT would occur if women were to use oestrogenonly MHT exclusively, rather than using combined oestrogen-progestogen MHT. Our calculations suggest that while this may result in a small increase in numbers of endometrial and ovarian cancers, these increases would be offset by a larger reduction in the numbers of breast cancers. Thus, recommendations that women with a uterus always be given combined MHT should be reassessed.
It is possible that concomitant use of progestogen-releasing intrauterine devices would mitigate the proliferative effect of oestrogen-only MHT on the endometrium, but how these devices influence breast or ovarian cancer risk is not clear, although at least one study using linked data from Finland suggests their use may be associated with a small increase in risk of breast cancer.
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Notwithstanding the likely imprecision, our results indicate that more than 500 cancers could have been prevented in 2010 if women did not use MHT. The decline in use since 2002 has almost certainly reduced cancer incidence, but a further reduction in use may be warranted especially in light of other known risks associated with MHT such as stroke and pulmonary embolus.
MHT is now mostly indicated for relief of perimenopausal/menopausal symptoms and, while undoubtedly effective for those indications, our results -in combination with information from other studies and guideline recommendations 2 -suggest that use of these therapies requires careful appraisal of the risks and benefits, and that if MHT is used it should be at the lowest dose that helps symptoms and for the shortest time.
